Table 2.
Pharmacokinetic parameters obtained for the indicated dosing regimens in the in vitro PK/PD model
| Parameter | Value with indicated dosing regimen |
|||||
|---|---|---|---|---|---|---|
| Oritavancin |
Daptomycin |
Vancomycin |
||||
| 1,200-mg single dose |
6 mg/kg once daily |
1,000 mg q12h |
||||
| Targeteda | Obtained | Targetedb | Obtained | Targetedc | Obtained | |
| ƒCmax (μg/ml) | 19.4 | 19.8 ± 2.0 | 8 | 7.6 ± 0.3 | 15 | 15.4 ± 0.7 |
| Half-life (h) | NDd | ND | 8 | 7.0 ± 0.3 | 6 | 5.9 ± 0.7 |
| ƒAUC0–24 | 138.1 | 136.8 ± 25.9 | ND | ND | ND | ND |
a
The mean population PK model was used to derive the targeted PK values from 2,000 simulated patients receiving a single 1,200-mg dose of oritavancin during a 3-h infusion (assuming protein binding of 85%).
b
The targeted PK values for daptomycin were derived from the full prescribing information (assuming protein binding of 91.5%) (Cubicin prescribing information [http://www.cubicin.com/pdf/PrescribingInformation.pdf]).
c
The targeted PK values for vancomycin were obtained from reference 9.
d
ND, not determined.